SITC 2021 | Targeting Siglec-15 with NC318 in Siglec-15-positive advanced solid tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, outlines the clinical benefit of targeting Siglec-15 with the monoclonal antibody NC318 in patients with Siglec-15-positive advanced solid tumors. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.